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Abstract
The characterization of biodistribution is a central requirement in the development of
biomedical applications based on the use of nanoparticles, in particular for controlled drug
delivery. The blood circulation time, organ biodistribution and rate of excretion must be well
characterized in the process of product development. In this work, the biodistribution of
recently developed self-assembled dextrin nanoparticles is addressed. Functionalization of the
dextrin nanoparticles with a DOTA-monoamide-type metal chelator, via click chemistry, is
described. The metal chelator functionalized nanoparticles were labelled with a γ -emitting
153Sm3+ radioisotope and the blood clearance rate and organ biodistribution of the
nanoparticles were obtained. The effect of PEG surface coating on the blood clearance rate and
organ biodistribution of the nanoparticles was also studied.
S Online supplementary data available from stacks.iop.org/Nano/21/295103/mmedia
1. Introduction
Nanomedicine has emerged in recent years as an exciting
area for chemists, materials scientists, engineers and medical
doctors, converging in the development of new tools for
diagnostics and therapeutics [1–3]. A rather large number
of nanostructures have been developed over the past few
decades. Well-defined polymeric nanostructures, on the
same size scale as proteins and cellular structures, are
promising vehicles for diagnostics and drug delivery [4].
The capability to carry and release a therapeutic payload
in a controlled way, coupled to imaging ability opens the
way to theragnostics [5]. A major limitation in the use of
(polymeric) nanoparticles in vivo is their premature elimination
from the circulatory system by the mononuclear phagocyte
system (MPS), which prevents the nanoparticles from reaching
their target [6]. The disposal of particles through the MPS
begins with the adsorption of serum proteins (opsonins) onto
the surface of the nanoparticles, followed by macrophage
recognition, phagocytosis, and subsequent sequestration in the
liver, spleen, and/or bone marrow. To address these limitations,
several methods have been developed to mask or camouflage
nanoparticles from the MPS. Among these, the preferred one
is the grafting of poly(ethylene glycol) (PEG) onto the surface
of nanoparticles [7]. The purpose of the PEG chains is to
block the adhesion of opsonins present in the blood serum,
such that the particles remain invisible to phagocytic cells.
Using transmission electron microscopy, it has been possible
to visualize the protein rejecting capabilities of PEGylated
surfaces [8]. PEG 5000 has proved to be a threshold for
maximum reduction of protein adsorption [9] and lower uptake
in the liver [10].
In recent years, the Michael addition of thiols to acrylates,
acrylamides and vinyl sulfones has acquired the status of a click
reaction: it can be performed selectively under mild (aqueous)
conditions. The major disadvantage of this reaction in
comparison to the dipolar addition of azides to terminal alkynes
is the possibility of thiol oxidation to disulfide and its inherent
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lack of bio-orthogonality, deriving from many endogenous
thiols [11, 12]. Recently, our research group has reported the
preparation of the acrylate ester functionalized dextrin: dexVA.
The Michael addition of hexadecanethiol to dexVA generates
an amphiphilic material, dexC16, which self-assembles in
water into well-defined nanoparticles, stable macromolecular
micelles (nanogel) [13]. Importantly, the dexC16 nanoparticles
can be loaded with a hydrophobic cargo, e.g., curcumin (anti-
cancer drug), for drug delivery purposes [14, 15].
To evaluate the potential of the dexC16 nanogel for drug
delivery purposes, the nanogel was labelled, via Michael
addition of a thiol functionalized fluorescent probe to the
acrylate groups, and its blood clearance was studied in BALB/c
mice [16]. Although the blood clearance of the nanogel
could be readily followed by fluorescence measurements, its
organ distribution profile could not be evaluated, possibly due
to quenching effects of the fluorescent probe in the organ’s
homogenates. It is widely accepted that the physical and
chemical properties of the nanoparticles, including particle
size, surface charge, and surface hydrophilicity, are important
parameters determining their biological fate after intravenous
administration [17]. It is, therefore, crucial to devise a labelling
methodology that conserves the native nanoparticle properties.
To obtain the biodistribution profile of the nanoparticles in
experimental animals, we envisaged labelling the nanogel with
a radioactive label. With this goal, we have synthesized a new
ω-thiol functionalized DOTA-monoamide-type metal chelator
(DOTA=1,4,7,10-tetraazacyclododecanetetraacetic acid) for
covalent functionalization (via Michael addition) and labelling
(complexation) of a suitable Ln3+ (e.g., 153Sm3+) radioisotope.
DOTA-like chelators are well known to form lanthanide(III)
chelates of high thermodynamic and kinetic stability, which is
of crucial importance for in vivo applications [18].
In the present study, the biodistribution and blood
clearance of dextrin nanoparticles labelled with 153Sm3+–
DOTA-type chelates has been studied in experimental
animals after intravenous administration. The effect of
surface decoration with PEG on the biodistribution was also
evaluated.
2. Experimental section
2.1. Materials
Dextrin-VA (dexVA) and dextrin-VA-SC16(dexC16) were
synthesized as comprehensively described before [13]. DexVA
is the dextrin backbone with grafted acrylate ester groups
(VA—vinyl acrylate). DexC16 is composed by the hydrophilic
dextrin backbone with grafted VA groups, which are
partially substituted with long alkyl chains (SC16). In this
work, dexC16 with 13 acrylate groups (DSVA 13%) and
6 hexadecanethioalkyl chains (DSC16 6%) per 100 dextrin
glucopyranoside residues was used.
O-[2-(3-mercaptopropionylamino)ethyl]-O′-methylpolye-
thylene glycol 5000 (PEG-SH), europium (III) chloride hex-
ahydrate 99.99%, samarium (III) chloride hexahydrate 99%
(SmCl3), dimethyl sulfoxide (DMSO), triethylamine (TEA)
and deuterium oxide (D2O) were purchased from Aldrich.
Regenerated cellulose tubular membranes, with 3500 MWCO,
were obtained from Membrane Filtration Products.
153SmCl3 was produced at the Instituto Tecnolo´gico e
Nuclear, Lisbon, Portugal with a specific radioactivity of
>5 GBq mg−1. For this purpose, 153Sm2O3 was prepared from
a 98% 152Sm enriched Sm2O3 target, sealed into a quartz vial
and welded into an aluminium can, by neutron irradiation using
a thermal flux of 2.3 × 1013 n cm−2 s−1. After irradiation,
the sample was opened, dissolved in 1 M HCl, and the final
153SmCl3 solution was brought to a stock concentration of
1.9 × 10−3 M.
2.2. Synthesis of ω-thiol functionalized metal chelator
Synthesis of tris-tert-butyl 2,2′,2′′-(10-(2-((2-(4-mercaptobut-
anamido)ethyl)amino)-2-oxoethyl)-1,4,7,10-tetraazacyclodod-
ecane-1,4,7-triyl)triacetate (3) (scheme 1): to a solution of
compound 2 (430 mg, 0.70 mmol) in methanol (30 cm3)
was added triethylamine (0.17 cm3, 1.2 mmol) and γ -
butyrothiolactone (0.61 g, 6.0 mmol). The reaction mix-
ture was stirred at 50 ◦C under a nitrogen atmosphere for
6 h and left stirring at room temperature overnight. The
reaction mixture was concentrated under reduced pressure
and the residue was purified by a flash chromatography
(100% CH2Cl2 → CH2Cl2/EtOH (70:30)) to afford the
title compound (3) as a colourless oil (0.162 g, 32%).
1H NMR (300 MHz, D2O): δ = 1.46 (s, 27H, tert-
Bu), 1.97 (m, 2H, C(O)CH2CH2CH2SH), 2.49 (m, 2H,
C(O)CH2CH2CH2SH), 2.57 (m, 2H, C(O)CH2CH2CH2SH),
2.20–3.80 (broad, overlapped signals with a integration
corresponding to approximately 28 H, N(CH2)2N, NCH2C(O)
and C(O)NHCH2CH2NHC(O)), 8.2 and 8.6 (broad signals,
C(O)NHCH2CH2NHC(O)).
Synthesis of 2,2′,2′′-(10-(2-((2-(4-mercaptobutanamido)-
ethyl)amino)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,
7-triyl)triacetic acid (4): compound (3) (162 mg, 226 μmol)
was dissolved in a mixture ethanol/aqueous HCl 6 M (1/1 v/v;
20 cm3) and left to stirring overnight at room temperature.
The solution was concentrated under reduced pressure and
further dried under vacuum to afford the title compound
(4), in the hydrochloride form, as a white vitreous solid
(121 mg). 1H NMR (300 MHz, D2O): δ = 1.88 (m,
2H, J = 7.5 Hz, C(O)CH2CH2CH2SH), 2.38 (t, 2H, J =
7.5 Hz, C(O)CH2CH2CH2SH), 2.54 (t, J = 6.9 Hz, 2H,
C(O)CH2CH2CH2SH), 3.00–3.70 (broad, overlapped signals
with a integration corresponding to approximately 28 H,
N(CH2)2N, NCH2C(O) and C(O)NHCH2CH2NHC(O)). 13C
NMR (75.4 MHz, D2O): 24.82 (C(O) CH2CH2CH2SH),
34.34 (C(O) CH2CH2CH2SH), 37.12 (C(O) CH2CH2CH2SH),
38.61 (CH2), 38.83 (CH2), 39.88 (CH2), 41.74 (CH2), 48.21
(CH2), 48.84 (CH2), 50.54 (CH2), 51.30 (CH2), 51.57 (CH2),
53.49 (CH2), 55.71 (CH2), 55.83 (CH2), 56.50 (CH2), 170.66
(C(O)OH), 173.25 (C(O)OH), 174.92 (C(O)NH), 176.42
(C(O)NH). MS (ESI-LR): m/z (%): 577.5 (18), 571.5 (66.5)
[M + Na]+, 549.5 (100) [M + Na]+, 447.5 (5).
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Scheme 1. Synthesis of the ω-thiol functionalized metal chelator DOTA-butyramide (4) and its Eu3+ complex (5):
(a) γ -butyrothiolactone/TEA/MeOH; (b) HCl/EtOH; (c) EuCl3·6H2O.
Scheme 2. Synthesis of the DOTAdexC16 and DOTAdexC16PEG and its Eu3+ complexes.
2.3. Preparation of DOTAdexC16 or DOTAdexC16PEG
materials
In the first step dexVA was reacted with the ω-thiol-
functionalized metal chelator (4) to afford the metal chelator
grafted material. In the second step, hexadecanethiol was
added to the former material to afford the DOTAdexC16
material (9). Finally, a thiol functionalized PEG molecule was
added to produce the DOTAdexC16PEG material (11).
DexVA is the dextrin backbone with grafted acrylate ester
groups (VA—vinyl acrylate). For the sake of simplicity,
in scheme 2, the grafted acrylate groups are represented at
position 2 of the glucopyranoside ring (major regioisomer),
although grafting in position 3 (minor regioisomer) can be
detected by 1H NMR, as reported before [19]. DexC16 is
composed by the hydrophilic dextrin backbone with grafted VA
groups, which are partially substituted with hexadecanethiol
chains (SR = hexadecanethiol). In this work, dexC16(8) with
13 acrylate groups (DSVA 13%) and 6-hexadecanethiol chains
(DSC16 6%) per 100 dextrin glucopyranoside residues was
used. For the sake of clarity the unreacted VA ester groups are
not shown on the materials (only substituted VA ester groups
are represented). DexVA (50 mg, DSVA 13%, 38.45 μmol
equivalent VA) was dissolved in DMSO (0.931 cm3). To
this solution was added a solution of compound 4 (11 mg,
19.23 μmol, 50% mol to VA groups) and triethylamine (16 μl,
0.115 mmol, 3 molar equivalents to VA groups). The medium
was stirred for 24 h, at 50 ◦C. In the second step the addition of
1-hexadecanethiol was performed as previously reported [13].
Briefly, hexadecanethiol (6) (7.95 mg, 30.76 μmol, 80%
relatively to VA groups) and triethylamine (11 μl, 38.45 μmol,
1 mol equivalent to VA groups) were added to the reaction
mixture. The medium was stirred for 24 h, at 50 ◦C.
The mixture was dialyzed for 48 h against water, with
frequent water changes. After freeze drying, material (9) was
obtained as a white candyfloss-like material and stored at room
temperature.
DOTAdexC16PEG (11) was obtained by dissolving
DOTAdexC16 (9) (15 mg, 12.2 μmol equivalent VA), PEG-SH
(18 mg, 3.66 μmol, 30% mol to VA groups) and triethylamine
(3.4 μl, 24.4 μmol, 2 mol equivalent to VA groups) in DMSO
(0.295 cm3). The mixture was stirred for 24 h, at 50 ◦C
and then dialyzed for 48 h against water, with frequent water
changes. After freeze drying, the product was obtained as a
white candyfloss-like material and stored at room temperature.
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2.4. Complexation of Eu3+ with ω-thiol functionalized
chelator and DOTAdexC16 materials
In order to ascertain the success of DOTA coupling to dexC16
and its chelating capacity, DOTAdexC16 or the soluble metal
chelator (4) were complexed with Eu3+ as a model metal ion.
The [Eu(DOTAdexC16)] complex was prepared by mixing a
solution of EuCl3·6H2O with a solution of DOTAdexC16 in
D2O. A slight excess (5%) of Eu3+ was used in relation to
the amount of metal chelator (4) used in the synthesis of the
DOTAdexC16 material. The reaction mixture was adjusted to
pH 5.5 by adding aqueous NaOD (0.1 mM) and was allowed
to react for 24 h at 50 ◦C. The reaction mixture was adjusted
to pH 7.0, filtered through a 0.2 μm filter and characterized by
1H NMR, DLS and zeta potential measurements.
The number of DOTA groups attached to the polymer
backbone was estimated by back titration of excess (uncom-
plexed) Eu3+ metal with EDTA in the presence of the complex-
ometric indicator, xylenol orange [20]. The amount of chelator
agent grafted to the dexC16 material was estimated 0.152 μmol
of DOTA chelator units/mg DOTAdexC16 material.
2.5. Preparation of [153Sm(DOTAdexC16)] and
[153Sm(DOTAdexC16PEG)] chelates for biodistribution
studies
To a dispersion of DOTAdexC16 or DOTAdexC16PEG (5 mg)
in sodium acetate buffer (400 μl, 0.4 M, pH 5) 153SmCl3
(1 mCi) was added. Each solution was stirred at 80 ◦C for
5 h. After that, cold SmCl3 was added to each solution in
order to obtain an equimolar Sm3+:DOTA ratio. The final
solution was heated at 80 ◦C for 2 h and stayed overnight
at room temperature. The radiolabelled nanoparticles were
purified using a Sephadex G-25 column eluted with 0.4 M
acetate buffer. The nanoparticle dispersions were concentrated
by centrifugal filtration (centricons, MWCO 10 kDa) to afford
the pure radioligands. The complexation yield is ca 50% in
both cases.
2.6. Size distribution and zeta potential
The size distribution and zeta potential of nanoparticles were
determined with a Malvern Zetasizer, NANO ZS (Malvern
Instruments Limited, UK), using a He–Ne laser (wavelength of
633 nm) and a detector angle of 173◦. Nanoparticle dispersion
(1 ml) was analyzed at 25 ◦C and 1.0 mg ml−1. The DLS
analysis provides the characterization of a sample through the
mean value (z-average) for the size and a width parameter
known as the polydispersity or polydispersity Index (PdI).
The z-average diameter is the mean hydrodynamic diameter,
determined from the intensity of scattered light, which can
be converted to other distributions. In the present work,
the z-average is considered the best approach to the actual
nanoparticles’ size. Nanoparticle dispersion was analyzed
in a polystyrene cell or in a folded capillary cell, for size
distribution or zeta potential measurements, respectively. The
zeta potential values were calculated using the Smoluchowski
equation [21]. Repeated measurements were performed for
each analysis (three times) and the values reported are average
values.
2.7. 1H NMR
Nanoparticles were dispersed in deuterium oxide
(10 mg ml−1). Dispersions were transferred to 5 mm
NMR tubes. 1D 1H NMR measurements were performed
with a VARIAN UNITY Plus 300 spectrometer operating at
299.94 MHz. 1D 1H NMR spectra were measured at 298 K
with 80 scans, a spectral width of 4800 Hz, a relaxation delay
of 1 s between scans and an acquisition time of 3.75 s.
2.8. Blood clearance and biodistribution studies
The biodistribution of dextrin nanoparticles labelled with
153Sm3+ was evaluated following intravenous administration
in Wistar rats. Groups of four animals were anaesthetized and
injected in the femoral vein with ca 100μl (20–100 μCi) of the
nanoparticles mixture. After pre-defined periods of time, the
rats were sacrificed and their tissues (liver, spleen, lungs, bone
(femur of left hind leg), intestines (small and large), kidney,
heart and brain) were excised, weighed and tissue radioactivity
measured in a γ well counter. Blood samples were obtained
at appropriate periods of time, weighted and radioactivity
counted. The same procedure was used to evaluate the
influence of the presence of PEG chains in the nanoparticles
biodistribution: a group of four animals was injected in
the femoral vein with the radiolabelled DOTAdexC16PEG
and sacrificed 2 h later for organ collection. The national
regulations for the care and use of laboratory animals have been
observed in this study.
3. Results and discussion
3.1. Synthesis of ω-thiol functionalized metal chelator
We have previously described the synthesis of the bifunctional
metal prochelator (2) bearing a functional amine group ready
for conjugation to (bio)molecules [22]. In this work, we
have used γ -butyrothiolactone as a protected activated ω-thiol
carboxylic acid equivalent (scheme 1). This procedure allows
performing the amide coupling without coupling reagents,
avoiding potential purification problems related to the removal
of the urea byproducts and auxiliary nucleophiles. Acidic
deprotection of the ω-thiol functionalized prochelator (3)
afforded the chelator (4), in the hydrochloride form, in an
aggregate 31% yield over two steps. DOTA-monoamide-
type metal chelators and its conjugates form Ln3+ complexes
of high thermodynamic and kinetic stability, as required for
in vivo studies, given the toxic effects of free (unchelated) Ln3+
ions.
3.2. Preparation of DOTAdexC16 or DOTAdexC16PEG
materials
With the ω-thiol functionalized DOTA synthon (4) on hand,
one can envisage two pathways for the synthesis of the
DOTAdexC16 material: either, performing first the Michael
addition of the ω-thiol functionalized metal chelator to the
acrylate functionalized dextrin (dexVA), followed by the
Michael addition of hexadecanethiol, or by reversing the
4
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a)
b)
c)
d)
7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5
f1 (ppm)
Figure 1. 1H NMR spectra of (a) dexC16, (b) DOTA-butyramide, (c) DOTAdexC16 and (d) DOTAdexC16PEG.
addition order. We have noted before, during the synthesis
of the dexC16 material, that even using a large molar excess
of hexadecanethiol in relation to the acrylate groups does
not give a full acrylate addition. Some acrylate groups
are much less reactive, possibly reflecting their grafting
position on the glucopyranoside ring and/or some degree of
steric hindrance. By first grafting the metal chelator to the
acrylate functionalized dextrin allows using a large excess of
hexadecanethiol (cheap, commercially available reagent) in the
second step in order to push the degree of substitution towards
the optimal value. We have established previously that the
dexC16 material with DSVA 13% and DSC16 6% is suitable for
forming stable nanoparticles within a narrow size range. In the
1H NMR spectrum of the dexC16 material (figure 1(a)) signals
assigned to the hexadecane moiety (δ = 0.75–1.75 ppm) are
clearly visible. The 1H NMR spectrum of the DOTAdexC16
material (figure 1(c)) displays a set of new broad low intensity
signals assigned to the grafted DOTA-butyramide chelator
(e.g., δ = 1.9, 2.4 and 2.7 ppm, assigned to the methylene
groups of the terminal mercaptobutyl moiety) as can be
inferred from the 1H NMR spectrum of the DOTA chelator
(figure 1(b)). Importantly, signals assigned to unreacted
acrylate groups on the dextrin backbone (δ = 6.0–6.6 ppm)
can also be seen in figures 1(a) and (c). The unreacted acrylate
groups allow further functionalization of the nanogel with thiol
functionalized PEG molecule. PEG grafting was confirmed by
disappearance of the signals (figure 1(d)) assigned to unreacted
acrylate ester groups and the appearance of a new intense
signal (δ = 3.6 ppm) assigned to the methylene groups of
the grafted PEG molecule. The 1H NMR spectrum of the
DOTAdexC16PEG material (figure 1(d)) displays new signals
assigned to the PEG moiety (δ = 3.4 and 3.6 ppm) confirming
the PEGylation of the nanoparticles.
3.3. Characterization of the nanoparticles
The DOTA coupling to the dextrin nanoparticles was used
as a tool to obtain a Ln3+ chelate which could be used
as (radioactive) label for biodistribution studies. The
high detection sensitivity of γ -emitting radioisotopes, e.g.,
153Sm3+, ensures that a low degree of substitution on
metal chelate allows sensitive detection, as required for
biodistribution studies. Moreover, the formation of neutral
Ln3+–DOTA-monoamide complexes ensures that the labelling
procedure does not substantially change the structure and/or
the overall (neutral) charge of the original (unlabelled)
nanoparticles, and therefore is not expected to interfere in the
biodistribution studies.
The size distribution and the zeta potential of the
nanoparticles from different materials were determined by
dynamic light scattering measurements (table 1).
As can be seen from table 1, the functionalization of the
nanoparticles with the DOTA metal chelator does not have a
substantial effect on the mean diameter of the nanoparticles.
For dexC16 the nanoparticles size increased from 23.9 to
25.3 nm, after coupling of the metal chelator. For dexC16PEG
a similar increase was observed, from 32.4 to 37.1 nm. In
contrast, the PEG functionalization increases substantially the
5
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Figure 2. Size distribution in intensity (%) of (——) dexC16 or (– – –) dexC16PEG in aqueous dispersion (1.0 mg ml−1).
a)
b)
34 32 30 28 26 24 22 20 18 16 14 12 10 8 6 4 2 0 -2 -4 -6 -8 -10 -12 -14-16 -18 -20
f1 (ppm)
Figure 3. 1H NMR spectra of (a) Eu(DOTA) and (b) [Eu(DOTAdexC16)].
Table 1. DLS analysis of the nanoparticles from different materials
in aqueous dispersion (1.0 mg ml−1), pH 7.0.
Material z-avg (nm) PdI Zeta potential (mV)
dexC16 23.9 0.388 −4.02
dexC16 PEG 32.4 0.442 −8.59
DOTAdexC16 25.3 0.341 −17.8
[Eu(DOTAdexC16)] — — −1.35
DOTAdexC16 PEG 37.1 0.275 —
hydrodynamic diameter of the nanoparticles. Figure 2 shows
the size distribution obtained by DLS for the nanoparticles
from the dexC16 and dexC16PEG materials. PEG decoration
does not change the nanoparticle population distribution, only
a shift to larger sizes is observed, suggesting that PEGylation
does not change the nanoparticles structure. This is consistent
with the formation of an exterior hydrophilic PEG corona
projecting into the aqueous media. The observed increase in
nanoparticle’s size is similar to that observed for other types of
nanoparticles (e.g. gold nanoparticles) following grafting with
PEG 5000 [23].
The surface functionalization of the dexC16 nanoparticles
with PEG is expected to affect its interaction with proteins and
cells, and thus its fate in vivo. The PEG hydrophilic corona
may avoid the recognition and uptake of the nanoparticles
by the organs of the MPS increasing the blood circulation
half-life, as reported by other authors working on different
nanoparticulate materials [24].
Zeta potential measurements were carried out to evaluate
the nanoparticles’ surface charge. The change of the zeta
potential of the dexC16 nanoparticles, from a near neutral
value (−4.02 mV) to a negative value (−17.8 mV) at pH 7.0,
following functionalization with the metal chelator, confirms
the grafting of the metal chelator. The grafted DOTA-
monoamide macrocycle is expected to bear an overall negative
charge at pH 7.0. Moreover, after complexation of the
DOTAdexC16 nanoparticles with Eu3+, the zeta potential value
returns to a near neutral value, similar to that of the original
dexC16 nanoparticles [25], consistent with the formation of
neutral [Eu(DOTAdexC16)] complexes.
The 1H NMR spectrum of the [Eu(DOTAdexC16)]
material (figure 3(b)) confirms that the Eu3+ complexation
effectively occurred. In the NMR spectra of the Eu(DOTA-
butyramide) chelate (5) (figure 3(a)) and [Eu(DOTAdexC16)]
material (figure 3(b)) the CH2 resonances within the
macrocycle and pendant acetate display strong paramagnetic
6
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Figure 4. Blood clearance profile of radiolabelled nanoparticles. The error bars correspond to the standard deviation (N = 4).
shifts as reported before for glycoconjugates of Eu(DOTA-
monoamide) chelates [22]. The amount of metal chelator
grafted to the dexC16 material was estimated by back
titration of excess Eu3+ with EDTA in the presence of the
complexometric indicator xylenol orange: circa 0.152 μmol
of DOTA-butyramide per mg of DOTAdexC16 material.
The Eu3+ complexation was used as a model system for
the labelling of the nanoparticles with the radioisotope
153Sm3+ for biodistribution studies. These studies confirm
that nanoparticles’ features (size and surface potential) are
conserved after labelling. Consequently, the biodistribution of
the labelled nanoparticles is expected to be representative of
the original (unlabelled) nanoparticles.
3.4. Blood clearance and biodistribution studies
We have attempted previously to perform biodistribution
studies of the dexC16 nanoparticles, using FITC-labelled
dextrin nanoparticles [16]. Although succeeding in evaluating
the nanoparticles blood clearance, we failed in our attempts
to characterize the organ accumulation. In the present work,
labelling the nanoparticles with 153Sm3+ effectively allowed
us to study the nanoparticles blood clearance and to obtain the
biodistribution profile in vivo.
The blood clearance profile of 153Sm3+-labelled nanopar-
ticles in Wistar rats, after intravenous injection, is shown in
figure 4. The clearance of the nanoparticles from the systemic
circulation is relatively fast in the first hour, proceeding
afterwards at a lower rate. In the first 15 min, about 23%
of the nanoparticles were removed from the bloodstream. At
1 h after injection, 47% of the injected dose is still detected
in the bloodstream, followed by a further reduction 2 h later
to about 30%. The blood clearance profile obtained is very
similar to the one previously reported, using FITC-labelled
dextrin nanoparticles [16].
The organ biodistribution of the [153Sm(DOTAdexC16)] in
Wistar rats was evaluated at different time points. Figure 5
Figure 5. Biodistribution in ( ) liver, ( ) kidney and ( ) spleen of
Wistar rats 5 min, 30 min, 2 h, 3 h, 24 h after i.v. injection of
[153Sm(DOTAdexC16)] stated as the percentage of injected dose per
gram of organ (%ID/g). Results are the mean of four animals.
and table 2 (supplemental information—SI available at
stacks.iop.org/Nano/21/295103/mmedia) show representative
data stated as the percentage of the injected dose per gram of
tissue (%ID/g).
The radioactivity was located mainly in the liver, spleen
and kidneys (figure 5), with low %ID/g found in the
other organs (table 2, see SI available at stacks.iop.org/
Nano/21/295103/mmedia), in the time frame analyzed in
the experiment. These results suggest that the removal of
nanoparticles occurs by phagocytosis, since liver and spleen
are macrophage-rich organs, consistently with the previous
observation of in vitro internalization of nanoparticles by
macrophages [16]. The maximum activity detected in the liver
and spleen gradually increases from the first data obtained
(5 min), reaching its maximum 2 h after injection, parallelling
the decreasing profile of the blood activity (see above). The
reduction of activity observed after 2 h suggests that the
material does not accumulate in the organs, presumably being
metabolized and excreted. As can be seen in figure 5 there
7
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Figure 6. Comparison of the biodistribution in Wistar rats 2 h after
i.v. injection of ( ) [153Sm(DOTAdexC16)] or ( )
[153Sm(DOTAdexC16PEG)]. Results are the mean of four animals.
is some renal uptake of nanoparticles, and excretion in the
urine was detected (data not shown), thus reinforcing the
hypothesis of kidney filtration of the smallest nanoparticles.
Zhang et al, reported that 20 nm pegylated gold nanoparticles
are also excreted through renal filtration [23]. They assumed
that the samples of gold nanoparticles contained a small
fraction of nanoparticles with diameters <5 nm, which could
be excreted via the urinary system. In the current case, small
dextrin nanoparticles are also likely to be present in the fairly
polydisperse materials. Furthermore, it may be hypothesized
that the self-assembled material is flexible enough to cross the
renal filtration system, which would be expected to exclude
rigid nanoparticles of the same size range. It must be remarked
that only few studies are available reporting the biodistribution
of self-assembled polymeric nanoparticles; furthermore, the
existing studies do not include nanoparticles in the size range
used in this study.
To avoid a rapid blood clearance, the nanoparticles should
retard opsonization and macrophage recognition, which results
in sequestration by the MPS organs. The decoration with PEG
was tested in this work with the purpose of improving the
circulation time. Figure 6 compares the 2 h organ distribution
of labelled nanoparticles, coated or not with PEG.
The results obtained confirm the well documented stealth
effect: PEG reduces opsonization, presumably by steric
and hydration effects, improving blood circulation time and
reducing the accumulation in the liver and spleen [24].
The decoration with PEG increases significantly the
hydrodynamic diameter of the nanoparticles. Although larger
particles have been reported as being taken up faster by the
MPS [26], the increased size is, in the current case, effectively
counterbalanced by the PEG steric and hydration effects,
overall resulting in reduction of the uptake rate. In general,
pegylated nanoparticles were found to have a longer circulation
time than the non-pegylated ones.
4. Conclusion
Functionalization of dextrin nanoparticles with a metal chela-
tor allows the radioactive labelling of the nanoparticles. The
labelling process has no significant effect on the nanoparticles
size and surface charge; hence the biodistribution profile
obtained in Wistar rats following intravenous administration
is considered representative of the unmodified nanoparticles.
This strategy is appropriate for in vivo studies, combining a
highly sensitive detection technique with minor nanoparticle
modifications. The dexC16 nanoparticles display a charac-
teristic biodistribution profile, being mainly taken up by the
organs of the MPS-liver and spleen. The blood circulation time
extends to several hours, although the concentration is halved
in about 1 h. The functionalization of the nanoparticles with
PEG 5000 in this formulation improves their circulation time
in the bloodstream and reduces the accumulation in the liver
and spleen.
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